Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers

Title: Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
Authors: Shawn Flanagan; Sonia L. Minassian; Philippe Prokocimer
Source: Journal of Clinical Medicine, Vol 7, Iss 6, p 150 (2018)
Publisher Information: MDPI AG
Publication Year: 2018
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: antibiotics; drug interactions; oxazolidinone; infectious disease; acute bacterial skin infections; pharmacokinetics; Medicine
Description: Therapeutic doses of tedizolid phosphate, an oxazolidinone antibiotic, lack monoamine oxidase inhibition in vivo, potentially resulting in an improved safety profile versus other oxazolidinones. This randomized, double-blind, placebo-controlled, 2-period, 2-sequence, crossover, phase 1 study (NCT01577459) assessed the potential for pharmacokinetic (PK) interactions between tedizolid and pseudoephedrine. Eighteen healthy volunteers (age: 18–45 years) were block-randomized to 1 of 2 treatment sequences containing 2 treatment periods (tedizolid phosphate or placebo once daily for 4 days; single dose of pseudoephedrine 60 mg on day 5) separated by a 2-day washout. Median time to maximum plasma concentration for tedizolid and pseudoephedrine ranged from 3 to 4 h, regardless of treatment coadministration. Steady-state tedizolid had no effect on the PK of pseudoephedrine; geometric mean ratio and 90% confidence interval remained within the no-effect 0.8 to 1.25 boundaries. The maximum observed concentration of tedizolid decreased by approximately 14% when pseudoephedrine was coadministered; no changes in the area under the plasma concentration-time curve or the minimum observed plasma concentration occurred. All adverse events (AEs) were mild, and there were no serious AEs or study drug discontinuations. No meaningful PK interactions occurred between tedizolid and pseudoephedrine, and tedizolid was well tolerated when administered in conjunction with pseudoephedrine.
Document Type: article in journal/newspaper
Language: English
Relation: http://www.mdpi.com/2077-0383/7/6/150; https://doaj.org/toc/2077-0383; https://doaj.org/article/7f35fc8153a04a0fba5ebd33c41170e0
DOI: 10.3390/jcm7060150
Availability: https://doi.org/10.3390/jcm7060150; https://doaj.org/article/7f35fc8153a04a0fba5ebd33c41170e0
Accession Number: edsbas.84D7A7D6
Database: BASE